Homepage

Provide a global review of lung cancer screening clinical trials, implementation studies, and organized programs. This map facilitates policy-level discussions drawing from real-world implementation around the world and drives a community of learning around LDCT (Low Dose Computed Tomography) screening.

The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer.

Neoadjuvant therapies have unique advantages and opportunities in lung cancer and need further investigation. Currently, there is no established guidance on how to process and evaluate resected lung cancer specimens following neoadjuvant therapy in the setting of clinical trials and clinical practice. There is also a lack of precise definitions of the degree of pathologic response, including Major Pathologic Response (MPR) or Complete Pathologic Response (CPR). The IASLC PR Project was created to establish Pathologic Response (PR), Major Pathologic Response (MPR), and/or Complete Pathologic Response (CPR) in surgical resection specimens following neoadjuvant therapies as predictors of long-term clinical benefit in patients with resected stages I to III lung cancers. These recommendations are intended as guidance for clinical trials, although it is hoped they can be viewed as suggestions for good clinical practice outside of clinical trials, to improve the consistency of pathologic assessment of treatment response.